Hippo signaling pathway gives new insight into systemic sclerosis

Study focuses on Hippo signaling pathway as critical link between fibrosis, vascular dysfunction, and sex bias in systemic sclerosis

4:00 PM

Author | Valerie Goodwin

Illustration of a microscope
Credit: Jacob Dwyer, Justine Ross: Michigan Medicine

Systemic sclerosis causes the skin to tighten and harden resulting in a potentially fatal autoimmune condition that is associated with lung fibrosis and kidney disease. 

University of Michigan Health researchers have studied the pathology of systemic sclerosis to understand better the disease and identify key pathways in the disease process that can be targeted therapeutically.

A research team led by University of Michigan Health’s Dinesh Khanna, M.B.B.S., M.Sc.,  professor of rheumatology and Johann Gudjonsson, M.D., Ph.D., professor of dermatology, in collaboration with John Varga, M.D., professor and chief of rheumatology, characterized the major cellular sources of fibrosis in the skin of patients with systemic sclerosis skin, identifying myofibroblasts and a subset of endothelial cells as the major contributors.

The research examined the Hippo signaling pathway, an evolutionarily conserved signaling pathway that plays a complex role in cellular function as a major pathway promoting fibrosis in systemic sclerosis. 

By directly targeting the Hippo signaling pathway, the research team demonstrated a reversal of the pro-fibrotic responses in both myofibroblasts and endothelial cells.

The discovery of this function of the Hippo signaling pathway in systemic sclerosis ties back to prior work that identified a regulator of this pathway as a key driver of sex biased immune responses, providing evidence that may help explain why systemic sclerosis is much more common in women than men.

The findings reported in this paper showed a marked effect from the drug verteporfin, which targets the Hippo signaling pathway, and rapid reversal of the pro-fibrotic phenotype in both myofibroblasts and endothelial cells.

“Verteporfin is approved for treatment of a subtype of macular degeneration suggesting that it could be repurposed towards treating systemic sclerosis,” said Gudjonsson. 

“This work helps shift the focus towards a novel pathway that is a key driver of the major features observed in systemic sclerosis and has the potential to be able to move quickly to testing in clinical trials.”

Furthermore, the researchers believe the unique and comprehensive nature of the data generated in this project may become valuable to other investigators studying systemic sclerosis.

“This is something that Khanna and I aim to move towards creating a proof of concept trial in the near future for to test this theory and further advancements in systemic sclerosis treatment and care,” said Gudjonsson.

Additional authors include: From the University of Michigan: Feiyang Ma Pei-Suen Tsou, Danielle Ochocki, Mehrnaz Gharaee-Kermani, Olesya Plazyo, Xianying Xing, Joseph Kirma, Rachael Wasikowski, William D. Brodie, and J. Michelle Kahlenberg and  Allison C. Billi. 

Disclosure:  There is a patent pending on the use of verteporfin to treat systemic sclerosis.

Michigan Research Core: Advanced Genomics Core

Citation: “Systems-based identification of the Hippo pathways for promoting fibrotic mesenchymal differentiation in systemic sclerosis,” Nature Communications. DOI: doi.org/10.1038

Sign up for Health Lab newsletters today. Get medical tips from top experts and learn about new scientific discoveries every week by subscribing to Health Lab’s two newsletters, Health & Wellness and Research & Innovation.

Sign up for the Health Lab Podcast: Add us on SpotifyApple Podcasts or wherever you get you listen to your favorite shows.

 


More Articles About: Basic Science and Laboratory Research dermatology
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Related
Health Lab
Systemic Scleroderma Treatments: Where Are We Now?
A new and novel outcome measure is being used to determine effectiveness of new scleroderma treatments. Learn how Michigan Medicine is leading the way.  
Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories close up of orange and purple squiggle-looking cells merging and a little green in the middle
Health Lab
Researchers find metabolic mechanism that blocks immune response, immunotherapy in cancer
New research has discovered why some cancers don’t respond to immunotherapy treatment: A metabolite transporter within the tumor microenvironment blocks a key type of tumor cell death integral to immune response.
white mouse and brown mouse kissing green with noses touching background and seeing inside of their brains lighting up with red dot
Health Lab
Mapping the social lives of mice
A study hints at how complex introducing yourself to another can be, using a mouse model to uncover the brain processes behind nonsexual social approach and contact.
grey brain with purple dots
Health Lab
Brain network study reveals clues about dementia’s behavior changes
Dementia doesn’t just erode memory – it also changes behavior and mental health. A new study shows the brain’s salience network and tau protein may be involved.
purple cells attached and merging
Health Lab
Organoid model predicts bladder cancer treatment response
Researchers have developed a new model to help predict treatment response in patients with bladder cancer. 
pill bottle spilling yellow blue
Health Lab
Drug used for alcoholism shows potential for stopping inflammatory disease
A study shows that disulfiram, known for causing severe hangover symptoms by blocking alcohol breakdown, also inhibits the inflammatory NLRP3 complex.
blue cells close up with orangey see through circle going in and an explosion of bright yellow orange to the far left in that circle with purple circles floating in background
Health Lab
Researchers identify factor that drives prostate cancer-causing genes
Researchers have uncovered a key reason why a typically normal protein goes awry and fuels cancer. They found the protein NSD2 alters the function of the androgen receptor, an important regulator of normal prostate development.